Thoracic Neoplasms  >>  Perjeta (pertuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perjeta (pertuzumab) / Roche
NCT00063154: Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

Completed
2
51
US
Pertuzumab
Genentech, Inc.
Non-small Cell Lung Cancer
04/05
04/05
PENGUIN, NCT00855894: A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer

Checkmark In combination with erlotinib in pts with relapsed NSCLC
Jan 2014 - Jan 2014: In combination with erlotinib in pts with relapsed NSCLC
Checkmark P2 data
Apr 2012 - Apr 2012: P2 data
Completed
2
41
US, RoW
Pertuzumab, Perjeta, Erlotinib, Tarceva
Genentech, Inc., Roche Pharma AG
Non-Small Cell Lung Cancer
03/12
03/12

Download Options